Drug delivery start-ups recognize benefits of contract manufacturing: CPHI panel
Strong and effective partnerships with CDMOs are essential to success due to the complexity of manufacturing processes
Start-up biopharma companies in the drug delivery space will continue to heavily rely on contract manufacturing despite the growing complexity of their processes, according to experts on a live CPHI Discover panel on Wednesday.
Speaking at the session, Drug Delivery Start-Ups to Watch in 2021 and Beyond, Wayne Weiner, Principal Consultant at PharmaTech Solutions said that given the type of complexity of some drug delivery products, any partnerships with CDMOs had to be strategic in scope.
Jose Ochoa, Chief Business Officer, of biotech Altimmune -- which develops intranasal vaccines and therapeutics and liver disease treatments -- said his company does not have its own manufacturing and worked with a number of contract manufacturing organisations (CMOs) both for clinical stage and commercial stage.
“We are heavily invested with working with CMOs,” he told the CPHI audience. “It doesn’t mean that down the road at some point we wouldn’t want to have our own facility depending on demand and on the need. For example, if a certain customer wanted to have access to the manufacturing, we would definitely work with them either through the CMO or direct build of a facility.”
Ochoa said that an effective partnership with a CMO required having ‘skin in the game’: “I’m not talking about a typical, strictly bilateral partnership with a vendor where you pay for a product or service, I’m talking about where they are really going the extra mile to provide tremendous customer service to the point where you would call them a partner and not just a vendor.
“If you can develop that kind of relationship with your CMO, you’ve got a fighting chance to be successful; if you don’t and it’s just a binary transaction where the minute you find a better CMO, you’re going to leave, that’s probably not a long-term sustainable relationship.”
Mahmoud Ameri, VP R&D and co-founder at California-based Zosano Pharma said that before the company decided to use contract manufacturing for its intracutaneous microneedle system,” we got the spreadsheets out and looked at how much it would cost if we manufactured this commercially at Zosano’s facility in Freemont, California, versus contracting it out to [CDMO] Patheon, located in North Carolina.”
He said that the decision to outsource was simply a matter of it being cheaper: “The Bay area is super-expensive when it comes to manufacturing anything so we left the Freemont facility for R&D and making clinical trial materials out to Phase II.”
Don Zinn, VP US Business at Crossject, which has developed Zeneo, a needleless auto-injector, said he understood the rationale for wanting to do inhouse manufacturing: “When you take it into your own hands to make sure that you can manufacture your product then you don’t have to worry about anyone else.”
He said that while Crossject manufactured the unit itself, it was then sent on to its partner, Cenexi, for fill and finish.
“We’ve had that relationship for quite some time and now that we’re ramping up our manufacturing to 6 million unit per year, we are likely going to press on that partnership even harder,” he said.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance